ConcertAI/NeoGenomics CTO-H Software as a Service

ConcertAI and NeoGenomics have launched CTO-H, a joint software-as-a-service solution in hematological malignancies for research analytics, clinical trial design, and clinical trial operational optimization. CTO-H is a highly representative database of more than 370,000 hematological malignancy patients with clinical attributes, surveillance data over seven to 11 years, and biomarker testing results. CTO-H is a result of a collaboration announced by the companies in January 2024. Under the collaboration, ConcertAI will be deploying CTO-H as a SaaS solution within its CARAai cloud. NeoGenomics will provide services relating to the interpretation of specialized biomarkers and testing, and the ability to access specific clinical expertise, the companies said.